希罗达联合多西他赛对老年晚期胃癌患者近期临床疗效及生存率的影响

目的研究希罗达联合多西他赛治疗老年晚期胃癌患者的近期临床疗效及生存率。方法选择收治的52例老年晚期胃癌患者，随机分为希罗迭联合多西他赛组（A组，n=26）和希罗达联合奥沙利铂组（B组，n=26）。比较分析两组近远期疗效及毒副反应情况。结果A组有效率以及1、2和3年生存率分别为46．15％、42．31％、23．08％、11．54％，略高于B组的42．31％、38．46％、15．38％、7．69％，但差异无统计学意义（P〉O．05）。两组疾病进展时间以及恶心呕吐、腹泻、肝功能损伤、手足综合症、骨髓抑制的发生率比较，差异无统计学意义（P〉0．05），A组总平均生存时间和神经毒性发生率大于B组，差异有统计学意义（P〈O．05）。结论希罗达联合多西他赛对老年晚期胃癌临床疗效确定，毒副反应可耐受，对提高生存时间有优势。值得临床推荐。

Objective To observe xeloda combined with docetaxel in the treatment of elderly patients with advanced gastric cancer clinical efficacy and survival rate. Methods 52 cases of elderly patients with advanced gastric cancer in our hospital were chosen and randomly divided into two groups： capecitabine combined with docetaxel group （ group A, n=26 ） and Xeloda in combination with oxaliplatin group （ group B, n=26 ） . The two groups were compared with tile short - and long-term efficacy and toxic side effects. Results The survival rates of A group were 46.15%, 42.31%, 23.08%, 11.54%, was slightly higher than the B group of 42.31%, 38.46%, 15.38%, 7.69%, but had no significant difference in statistics （P〉0.05.） .In the two groups, the time of disease progression and the incidence of nausea, vomiting, diarrhea, liver injury, hand foot syndrome, bone marrow suppression were not significantly different （P〉0.05 ） . The total average survival time and neurotoxicity in A group were significantly higher than that in B group （ P〈0.05 ） . Conclusion Xeloda combined with docetaxel on elderly patients with advanced gastric cancer clinical efficacy sure, toxicity can be tolerated, improve the survival time of seems to have advantages, is worthy of recommendation.